How healthy is your heart?

摘要

MPO(myeloperoxidase)is an inflammatory biomarker that may show elevated levels in the plasma of patients suffering heart failure and cardiac dysfunction.With a rise in MPO appearing earlier than with other traditional cardiac biomarkers(such as troponin),MFC)offers new possibilities for early identification of cardiac events and,potentially,treatment before irreversible cell damage(necrosis)has occurred.Release of MPO can even precede myocardial injury and so identify at-risk patients.Here we examine its clinical use as a predictor of cardiovascular events.